Results 151 to 160 of about 895 (178)
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim [PDF]
Journal of Antimicrobial Chemotherapy, 2020 OBJECTIVES: Eumycetoma is currently treated with a combination of itraconazole therapy and surgery, with limited success. Recently, olorofim, the lead candidate of the orotomides, a novel class of antifungal agents, entered a Phase II trial for the ...
Wilson Lim +2 more
exaly +7 more sources
The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis [PDF]
Antimicrobial Agents and Chemotherapy, 2018 Olorofim (formerly F901318) is an advanced analog of the orotomide class that inhibits fungal pyrimidine biosynthesis. We evaluated the in vitro and in vivo activities of olorofim against Coccidioides species.
Nathan P Wiederhold
exaly +3 more sources
EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Olorofim is a novel antifungal agent with in vitro activity against Aspergillus and some other molds. Here, we addressed technical aspects for EUCAST olorofim testing and generated contemporary MIC data.
Rasmus Hare Jensen +1 more
exaly +4 more sources
Lancet Infectious Diseases, TheBackgroundOnly a small number of antifungal therapies for invasive fungal disease (IFD) are currently available, and many pathogens are resistant to one or more of these therapies. Olorofim, the first orotomide antifungal agent to be developed, is active
Catherine Orla Morrissey +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Olorofim Effectively Eradicates Dermatophytes In Vitro and In Vivo
Antimicrobial Agents and Chemotherapy, 2021Superficial fungal infections are prevalent worldwide, with dermatophytes as the most common cause. Various antifungal agents including azoles and allylamines are commonly used to treat dermatophytosis.
Esmat Mirbzadeh Ardakani +7 more
openaire +2 more sources
In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis
Antimicrobial Agents and Chemotherapy, 2021Clinically relevant members of the Scedosporium / Pseudallescheria species complex and Lomentospora prolificans are generally resistant against currently available systemic antifungal agents in vitro , and infection due to these species is ...
S. Seyedmousavi +6 more
openaire +2 more sources
Nature Microbiology, 2023 Abstract Widespread use of azole antifungals in agriculture has been linked to resistance in the pathogenic fungus Aspergillus fumigatus . We show that exposure of A. fumigatus to the agrochemical fungicide, ipflufenoquin, in vitro can
Norman van Rhijn +2 more
exaly +5 more sources
Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus [PDF]
Antimicrobial Agents and Chemotherapy, 2018 F901318 (olorofim) is a novel antifungal drug that is highly active against Aspergillus species. Belonging to a new class of antifungals called the orotomides, F901318 targets dihydroorotate dehydrogenase (DHODH) in the de novo pyrimidine biosynthesis pathway.
Saskia du Pré +2 more
exaly +4 more sources
Antimicrobial Agents and Chemotherapy, 2020 Olorofim is a novel antifungal drug in phase 2 trials. It has shown promising in vitro activity against various molds, except for Mucorales. Initially, we observed a broad range of EUCAST MICs for Aspergillus fumigatus .
Rasmus Hare Jensen +1 more
exaly +5 more sources